Kaposi's sarcoma: possible Foscarnet treatment? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Kaposi's sarcoma: possible Foscarnet treatment? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Treat News. 1995 Jan 20;(No 215):4-5. Unique Identifier : AIDSLINE AIDS/95700105
James JS

Abstract: Foscarnet (Foscavir), an antiviral used to treat CMV (cytomegalovirus) infection, is also used to treat acyclovir-resistant herpes simplex and all other herpesviruses. Foscarnet, an expensive treatment, has serious side effects, especially kidney toxicity. A laboratory study found evidence that Kaposi's sarcoma (KS) may be caused by a herpesvirus. When physicians noticed that KS regressed in two patients being treated with foscarnet for other purposes, a pilot study of five patients was conducted. Three of the five patients had a long-term remission of KS after a single 10-day treatment. The study, organized by Linda Morfeldt of the Karolinska Institute in Sweden, suggests that the effect of foscarnet on KS is not proven, that the drug may be effective in early KS, and that patients with ongoing active infections may not respond to foscarnet as a KS treatment. Other small studies are being organized. The experiences of persons with KS who have used foscarnet are covered.
Keywords: Foscarnet/*THERAPEUTIC USE Human HIV Infections/*COMPLICATIONS Sarcoma, Kaposi's/*DRUG THERAPY/ETIOLOGY NEWSLETTER ARTICLE REVIEW CLINICAL TRIALKWDfoscarnet/KWDtherapeuticusehumanhivinfections/KWDcomplicationssarcoma,kaposi's/KWDdrugtherapy/etiologynewsletterarticlereviewclinicaltrial
950530
M9551028

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .